Rheumatoid arthritis-associated lung disease

European Respiratory Review

Volumn 24, Issue 135, 2015, Pages 1-16

  Shaw, Megan ^a   Collins, Bridget F ^b   Ho, Lawrence A ^b   Raghu, Ganesh ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG SAFETY; HUMAN; INFECTION RISK; INFECTIOUS COMPLICATION; INTERSTITIAL LUNG DISEASE; LOWER RESPIRATORY TRACT; LUNG BIOPSY; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG NODULE; MEDICATION THERAPY MANAGEMENT; PATHOPHYSIOLOGY; PLEURA DISEASE; PLEURA FLUID; PNEUMOCYSTIS PNEUMONIA; PROGNOSIS; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SMOKING; THORAX RADIOGRAPHY; UPPER RESPIRATORY TRACT; VASCULAR DISEASE; COMPLICATION; LUNG DISEASES;

ARTHRITIS, RHEUMATOID; HUMANS; LUNG DISEASES;

EID: 84923885189     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00008014     Document Type: Article

References (123)

1. Marigliano B, Soriano A, Margiotta D, et al. Lung involvement in connective tissue diseases: a comprehensive review and a focus on rheumatoid arthritis. Autoimmun Rev 2013; 12: 1076–1084.
2. O’Dwyer DN, Armstrong ME, Cooke G, et al. Rheumatoid arthritis (RA) associated interstitial lung disease (ILD). Eur J Intern Med 2013; 24: 597–603.
3. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011; 183: 372–378.
4. Doyle TJ, Lee JS, Dellaripa PF, et al. A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease. Chest 2014; 145: 454–463.
5. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997; 156: 528–535.
6. Habib HM, Eisa AA, Arafat WR, et al. Pulmonary involvement in early rheumatoid arthritis patients. Clin Rheumatol 2011; 30: 217–221.
7. Cavagna L, Monti S, Grosso V, et al. The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. Biomed Res Int 2013; 2013: 759760.
8. Myasoedova E, Crowson CS, Turesson C, et al. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995–2007 versus 1985–1994: a population-based study. J Rheumatol 2011; 38: 983–989.
9. Bartels CM, Bell CL, Shinki K, et al. Changing trends in serious extra-articular manifestations of rheumatoid arthritis among United State veterans over 20 years. Rheumatology (Oxford) 2010; 49: 1670–1675.
10. de Lauretis A, Veeraraghavan S, Renzoni E. Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis 2011; 8: 53–82.
11. Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010; 62: 1583–1591.
12. Assayag D, Lubin M, Lee JS, et al. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology 2014; 19: 493–500.
13. Saag KG, Cerhan JR, Kolluri S, et al. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997; 56: 463–469.
14. Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol 2013; 25: 360–366.
15. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006; 65: 845–851.
16. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 380–386.
17. Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics–a large multicentre UK study. Rheumatology (Oxford) 2014; 53: 1676–1682.
18. Ytterberg AJ, Joshua V, Reynisdottir G, et al. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation. Ann Rheum Dis 2014 [in press DOI: 10.1136/annrheumdis-2013-204912].
19. Aubart F, Crestani B, Nicaise-Roland P, et al. High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol 2011; 38: 979–982.
20. Luukkainen R, Saltyshev M, Pakkasela R, et al. Relationship of rheumatoid factor to lung diffusion capacity in smoking and non-smoking patients with rheumatoid arthritis. Scand J Rheumatol 1995; 24: 119–120.
21. Tuomi T, Heliövaara M, Palosuo T, et al. Smoking, lung function, and rheumatoid factors. Ann Rheum Dis 1990; 49: 753–756.
22. Fischer A, Solomon JJ, du Bois RM, et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 2012; 106: 1040–1047.
23. Gizinski AM, Mascolo M, Loucks JL, et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol 2009; 28: 611–613.
24. Rangel-Moreno J, Hartson L, Navarro C, et al. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest 2006; 116: 3183–3194.
25. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 38–46.
26. Hill JA, Southwood S, Sette A, et al. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003; 171: 538–541.
27. Furukawa H, Oka S, Shimada K, et al. Association of human leukocyte antigen with interstitial lung disease in rheumatoid arthritis: a protective role for shared epitope. PLoS One 2012; 7: e33133.
28. Hallowell RW, Horton MR. Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced. Drugs 2014; 74: 443–450.
29. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35: 1322–1328.
30. Kim EJ, Collard HR, King TE. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 2009; 136: 1397–1405.
31. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
32. Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003; 58: 143–148.
33. Cottin V, Nunes H, Mouthon L, et al. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum 2011; 63: 295–304.
34. Cottin V, Cordier JF. Combined pulmonary fibrosis and emphysema in connective tissue disease. Curr Opin Pulm Med 2012; 18: 418–427.
35. Nakamura Y, Suda T, Kaida Y, et al. Rheumatoid lung disease: prognostic analysis of 54 biopsy-proven cases. Respir Med 2012; 106: 1164–1169.
36. Turesson C, Matteson EL, Colby TV, et al. Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum 2005; 52: 73–79.
37. Tsuchiya Y, Takayanagi N, Sugiura H, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 2011; 37: 1411–1477.
38. Ascherman DP. Interstitial lung disease in rheumatoid arthritis. Curr Rheumatol Rep 2010; 12: 363–369.
39. Roschmann RA, Rothenberg RJ. Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy. Semin Arthritis Rheum 1987; 16: 174–185.
40. Ogawa D, Hashimoto H, Wada J, et al. Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 1422–1424.
41. Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. J Korean Med Sci 2002; 17: 270–273.
42. Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 2009; 337: 329–335.
43. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40: 640–646.
44. Rojas-Serrano J, González-Velásquez E, Mejía M, et al. Interstitial lung disease related to rheumatoid arthritis: evolution after treatment. Reumatol Clin 2012; 8: 68–71.
45. Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014; 19: 353–359.
46. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011; 41: 256–264.
47. Yazdani A, Singer LG, Strand V, et al. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Heart Lung Transplant 2014; 33: 514–520.
48. Rajasekaran A, Shovlin D, Saravanan V, et al. Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis over 5 years. J Rheumatol 2006; 33: 1250–1253.
49. Solomon JJ, Ryu JH, Tazelaar HD, et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med 2013; 107: 1247–1252.
50. Balbir-Gurman A, Yigla M, Nahir AM, et al. Rheumatoid pleural effusion. Semin Arthritis Rheum 2006; 35: 368–378.
51. Corcoran JP, Ahmad M, Mukherjee R, et al. Pleuro-pulmonary complications of rheumatoid arthritis. Respir Care 2014; 59: e55–e59.
52. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 8-2002. A 56-year-old woman with a persistent left-sided pleural effusion. N Engl J Med 2002; 346: 843–850.
53. Faurschou P, Francis D, Faarup P. Thoracoscopic, histological, and clinical findings in nine case of rheumatoid pleural effusion. Thorax 1985; 40: 371–375.
54. Avnon LS, Abu-Shakra M, Flusser D, et al. Pleural effusion associated with rheumatoid arthritis: what cell predominance to anticipate? Rheumatol Int 2007; 27: 919–925.
55. Walker WC, Wright V. Rheumatoid pleuritis. Ann Rheum Dis 1967; 26: 467–474.
56. Chen JJ, Branstetter BF, Myers EN. Cricoarytenoid rheumatoid arthritis: an important consideration in aggressive lesions of the larynx. AJNR Am J Neuroradiol 2005; 26: 970–972.
57. Jurik AG, Pedersen U. Rheumatoid arthritis of the crico-arytenoid and crico-thyroid joints: a radiological and clinical study. Clin Radiol 1984; 35: 233–236.
58. Feraco P, Bazzocchi A, Righi S, et al. Involvement of cricoarytenoid joints in rheumatoid arthritis. J Clin Rheumatol 2009; 15: 264.
59. Greco A, Fusconi M, Macri GF, et al. Cricoarytenoid joint involvement in rheumatoid arthritis: radiologic evaluation. Am J Otolaryngol 2012; 33: 753–755.
60. Kolman J, Morris I. Cricoarytenoid arthritis: a cause of acute upper airway obstruction in rheumatoid arthritis. Can J Anaesth 2002; 49: 729–732.
61. Mori S, Koga Y, Sugimoto M. Small airway obstruction in patients with rheumatoid arthritis. Mod Rheumatol 2011; 21: 164–173.
62. Perez T, Remy-Jardin M, Cortet B. Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. Am J Respir Crit Care Med 1998; 157: 1658–1665.
63. Shen TC, Lin CL, Chen CH, et al. Increased risk of chronic obstructive pulmonary disease in patients with rheumatoid arthritis: a population-based cohort study. QJM 2014; 107: 537–543.
64. Fuld JP, Johnson MK, Cotton MM, et al. A longitudinal study of lung function in nonsmoking patients with rheumatoid arthritis. Chest 2003; 124: 1224–1231.
65. Hayakawa H, Sato A, Imokawa S, et al. Bronchiolar disease in rheumatoid arthritis. Am J Respir Crit Care Med 1996; 154: 1531–1536.
66. Kinoshita M, Higashi T, Tanaka C, et al. Follicular bronchiolitis associated with rheumatoid arthritis. Intern Med 1992; 31: 674–677.
67. Devouassoux G, Cottin V, Liote H, et al. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J 2009; 33: 1053–1061.
68. Lynch JP, Weigt SS, DerHovanessian A, et al. Obliterative (constrictive) bronchiolitis. Semin Respir Crit Care Med 2012; 33: 509–532.
69. Penny WJ, Knight RK, Rees AM, et al. Obliterative bronchiolitis in rheumatoid arthritis. Ann Rheum Dis 1982; 41: 469–472.
70. Cortot AB, Cottin V, Miossec P, et al. Improvement of refractory rheumatoid arthritis-associated constrictive bronchiolitis with etanercept. Respir Med 2005; 99: 511–514.
71. Cortet B, Flipo RM, Remy-Jardin M, et al. Use of high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1995; 54: 5.
72. Wilczynska MM, Condliffe AM, McKeon DJ. Coexistence of bronchiectasis and rheumatoid arthritis: revisited. Respir Care 2013; 58: 8.
73. Cohen M, Sahn SA. Bronchiectasis in systemic diseases. Chest 1999; 116: 1063–1074.
74. Puéchal X, Fajac I, Bienvenu T, et al. Increased frequency of cystic fibrosis deltaF508 mutation in bronchiectasis associated with rheumatoid arthritis. Eur Respir J 1999; 13: 1281–1287.
75. Gupta P, Ponzo F, Kramer EL. Fluorodeoxyglucose (FDG) uptake in pulmonary rheumatoid nodules. Clin Rheumatol 2005; 24: 402–405.
76. Combe B, Didry C, Gutierrez M, et al. Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis. Eur J Med 1993; 2: 153–156.
77. MacMahon H, Austin JHM, Gamsu G, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005; 237: 395–400.
78. Chhakchhuak CL, Khosravi M, Lohr KM. Role of 18F-FDG PET scan in rheumatoid lung nodule: case report and review of the literature. Case Rep Rheumatol 2013; 2013: 621340.
79. Schreiber J, Koschel D, Kekow J, et al. Rheumatoid pneumoconiosis (Caplan’s syndrome). Eur J Intern Med 2010; 21: 168–172.
80. Shahane A. Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis. Rheumatol Int 2013; 33: 1655–1667.
81. Udayakumar N, Venkatesan S, Rajendiran C. Pulmonary hypertension in rheumatoid arthritis–relation with the duration of the disease. Int J Cardiol 2008; 127: 410–412.
82. Keser G, Capar I, Aksu K, et al. Pulmonary hypertension in rheumatoid arthritis. Scand J Rheumatol 2004; 33: 244–245.
83. Dawson JK, Goodson NG, et al. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology (Oxford) 2000; 39: 1320–1325.
84. Chung WS, Peng CL, Lin CL, et al. Rheumatoid arthritis increases the risk of deep venous thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis 2014; 73: 7.
85. Bacani AK, Gabriel SE, Crowson CS, et al. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum 2012; 64: 9.
86. van den Oever IA, Sattar N, Nurmohamed MT. Thromboembolic and cardiovascular disease in rheumatoid arthritis: role of the haemostatic system. Ann Rheum Dis 2014; 73: 954–957.
87. Liang KP, Liang KV, Matteson EL, et al. Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum 2006; 54: 642–648.
88. Jani M, Hirani N, Matteson EL, et al. The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol 2014; 10: 284–294.
89. Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 2014; 43: 613–626.
90. Saravanan V, Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 787–789.
91. Barrera P, Laan RF, van Riel PL, et al. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 434–439.
92. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000; 15: 373–381.
93. Dawson JK, Graham DR, Desmond J, et al. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 2002; 41: 262–267.
94. Cottin V, Tebib J, Massonnet B, et al. Pulmonary function in patients receiving long term low dose methotrexate. Chest 1996; 109: 933–938.
95. Conway R, Low C, Coughlan RJ, et al. Methotrexate and lung disease in rheumatoid arthritis–a meta-analysis of randomized controlled trials. Arthritis Rheum 2014; 66: 803–812.
96. Carroll GJ, Thomas R, Phatouros CC, et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 1994; 21: 51–54.
97. Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 1997; 127: 356–364.
98. Furukawa H, Oka S, Shimada K, et al. HLA-A*31:01 and methotrexate-induced interstitial lung disease in Japanese rheumatoid arthritis patients: a multidrug hypersensitivity marker? Ann Rheum Dis 2013; 72: 153–155.
99. Namba T, Tanaka KI, Ito Y, et al. Induction of EMT-like phenotypes by an active metabolite of leflunomide and its contribution to pulmonary fibrosis. Cell Death Differ 2010; 17: 1882–1895.
100. Ju JH, Kim SI, Lee JH, et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 2094–2096.
101. Hadjinicolaou AV, Nisar MK, Bhagat S, et al. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases–a systematic literature review. Rheumatology (Oxford) 2011; 50: 2297–2305.
102. Lager J, Hilberg O, Løkke A, et al. Severe interstitial lung disease following treatment with certolizumab pegol: a case report. Eur Respir Rev 2013; 22: 414–416.
103. Herrinton LJ, Harrold LR, Liu L, et al. Association between anti-TNF-α therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf 2013; 22: 394–402.
104. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31: 456–473.
105. Hainsworth JD. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. Arthritis Res Ther 2003; 5: Suppl. 4, S12–S16.
106. Soubrier M, Jeannin G, Kemeny JL, et al. Organizing pneumonia after rituximab therapy: two cases. Joint Bone Spine 2008; 75: 362–365.
107. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390–1400.
108. Scott DL, Bradby GV, Aitman TJ, et al. Relationship of gold and penicillamine therapy to diffuse interstitial lung disease. Ann Rheum Dis 1981; 40: 136–141.
109. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987–997.
110. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 1761–1769.
111. Kawashiri SY, Kawakami A, Sakamoto N, et al. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int 2012; 32: 4023–4026.
112. Wendling D, Vidon C, Godfrin-Valnet M, et al. Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis. Joint Bone Spine 2013; 80: 670–671.
113. Wada T, Akiyama Y, Yokota K, et al. [A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of abatacept]. Nihon Rinsho Meneki Gakkai Kaishi 2012; 35: 433–438.
114. Seeger W, Adir Y, Barbera JA, et al. Pulmonary hypertension in chronic lung disease. J Am Coll Cardiol 2013; 62: Suppl. 25, D109–D116.
115. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population based study. Arthritis Rheum 2002; 46: 2293.
116. Coyne P, Hamilton J, Heycock C, et al. Acute lower respiratory tract infection in patients with rheumatoid arthritis. J Rheumatol 2007; 34: 1832–1836.
117. Blumentals WA, Arreglado A, Napalkov P, et al. Rheumatoid arthritis and the incidence of influenza and influenze related complications: a retrospective cohort study. BMC Musculoskelet Disord 2012; 13: 158.
118. Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in the USA. Ann Rheum Dis 2013; 72: 37–42.
119. Dixon WG, Suissa S, Hudson M. The association between syetemic glucocorticoid therapy and the risk of infection inpatients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther 2011; 13: R139.
120. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148–155.
121. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098–1104.
122. Kaiser R. Incidence of lymphoma in patients with rheumatoid arthritis: a systematic review of the literature. Clin Lymphoma Myeloma 2008; 8: 87–93.
123. Silman AJ, Petrie J, Hazelman B, et al. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988; 47: 988–992.